U.S., Dec. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07287228) titled 'The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia' on Sept. 25.
Brief Summary: This study consists of two phases, phase Ib and phase II. The primary objective of phase Ib is to evaluate the safety and tolerability of multiple doses of daratumumab in patients with refractory aplastic anemia. The primary objective of phase II is to preliminarily assess the efficacy of multiple doses of daratumumab in patients with refractory aplastic anemia. Secondary objectives include evaluation of other efficacy endpoints, safety (phase II), and pharmacodynamic characteristics of multiple doses of daratumumab in the...